Search Results
10
Everything
Search Filters
Organization
Longeveron
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
March 20, 2025 09:00 ET
|
Longeveron
Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
March 11, 2025 08:30 ET
|
Longeveron
Longeveron positive Phase 2 clinical trial data in Alzheimer's disease published in peer reviewed journal Nature Medicine.
Longeveron® to Present at the 37th Annual Roth Conference
March 05, 2025 09:25 ET
|
Longeveron
Longeveron to present at the Roth investor conference taking place March 17-18, 2025. Company fireside chat Tuesday, March 18th at 9:00am PT.
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
February 28, 2025 16:04 ET
|
Longeveron
Longeveron announces 2024 financial results and provides business update. Pivotal Phase 2b clinical trial achieves 90% enrollment.
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
February 21, 2025 08:30 ET
|
Longeveron
Longeveron to report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close.
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
February 18, 2025 09:25 ET
|
Longeveron
WHO approved generic name laromestrocel for stem cell therapy Lomecel-B, being developed as potential treatment for Alzheimer's disease and HLHS.
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
February 14, 2025 09:05 ET
|
Longeveron
Longeveron to present at the Emerging Growth Virtual Conference taking place February 18-19, 2025.
Longeveron to Present at Biotech Showcase 2025
December 18, 2024 09:10 ET
|
Longeveron
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
December 02, 2024 09:05 ET
|
Longeveron
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET
|
Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.